Failing to provide additional protection against cisplatin toxicity after knockdown of the STAT1 gene in mice (Schmitt et al., 2009); EGCG reduced cisplatin-induced ROS generation and ERK1/2 and STAT1 activity, but retained STAT3 and Bcl-xL activity, allowing cisplatin to continue its anti-tumour effects (Borse et al., 2017). The gene discussed is STAT1; the disease is neoplasm.